1. Home
  2. LTH vs CYTK Comparison

LTH vs CYTK Comparison

Compare LTH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Life Time Group Holdings Inc.

LTH

Life Time Group Holdings Inc.

N/A

Current Price

$44.71

Market Cap

9.4B

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$62.51

Market Cap

10.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LTH
CYTK
Founded
1992
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.4B
10.7B
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
LTH
CYTK
Price
$44.71
$62.51
Analyst Decision
Strong Buy
Buy
Analyst Count
15
22
Target Price
$57.60
★ $107.39
AVG Volume (30 Days)
★ 3.0M
1.6M
Earning Date
10-29-2026
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 124.32
N/A
EPS
★ 1.30
N/A
Revenue
★ $2,995,255,000.00
$13,368,000.00
Revenue This Year
$12.97
$79.67
Revenue Next Year
$11.89
$172.23
P/E Ratio
$33.86
★ N/A
Revenue Growth
★ 14.28
N/A
52 Week Low
$24.46
$58.05
52 Week High
$47.32
$88.31

Technical Indicators

Market Signals
Indicator
LTH
CYTK
Relative Strength Index (RSI) 60.13 45.85
Support Level $41.74 $59.21
Resistance Level $43.96 $67.65
Average True Range (ATR) 1.56 1.77
MACD 0.35 0.41
Stochastic Oscillator 55.44 48.20

Price Performance

Historical Comparison
LTH
CYTK

About LTH Life Time Group Holdings Inc.

Life Time Group Holdings Inc is a lifestyle and leisure brand offering health, fitness, and wellness experiences to a community. It is engaged in designing, building, and operating distinctive and large, multi-use sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in residential locations of metropolitan areas in the United States and Canada.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: